Details
Join us for an insightful session exploring the rising global impact of diabetes and obesity, and how incretin-based therapies like GLP-1 and GIP receptor agonists are transforming treatment strategies. Discover the science behind these hormones, their growing market potential, and the future of dual agonist therapies in metabolic health.
We will explore the pharmacodynamics of receptor agonists, their preclinical efficacy in glycemic control and weight management, and the evolving landscape of dual agonist therapies. The session will also highlight market trends, translational research opportunities, and emerging therapeutic targets.
Our screening platform for your research needs:
- In vitro assays
- Pharmacokinetic profiling tools
- Proof of concept for efficacy screening
- Preclinical toxicology studies
Whether you are a healthcare professional, researcher, or industry stakeholder, this webinar offers valuable perspectives on one of the most pressing health challenges of our time.
*In vivo studies conducted with our partner laboratory – Adgyl Lifesciences
Speakers
Ritika U
Ritika U Assistant Director Eurofins Advinus BioPharma Services India Private Limited Eurofins Advinus BioPharma Services India Private LimitedDr. Ritika Uppal Mukherjee holds a Ph.D. in Bio-inorganic Chemistry from Yale University, USA, and completed her postdoctoral research at the Martinos Center, affiliated with Massachusetts General Hospital and Harvard Medical School. She has authored 17 publications in high-impact international journals and presented at numerous global conferences. Dr. Mukherjee currently leads the in vitro ADME and pharmacology division at Eurofins Advinus. Her expertise includes physico-chemical profiling, metabolism and biotransformation, permeability and drug transporter assays, and drug-drug interaction studies. She has played a pivotal role in elucidating metabolite structures and mapping metabolic pathways for over 70 novel drug candidates.
Suhas Tambe
Suhas Tambe Section Head Adgyl Lifesciences Private LimitedAdgyl Lifesciences Private LimitedMr. Suhas Tambe is a pharmacologist by training from MS University, Baroda, with over 20 years of experience in drug discovery and the CRO space. His expertise spans multiple therapeutic areas, including metabolic, cardiovascular, fibrosis, gastrointestinal, and ocular disorders, with proven capability to develop customized models as per project requirements. He has collaborated on numerous drug discovery programs targeting diverse mechanisms with leading pharmaceutical companies. Mr. Tambe has authored more than 10 publications in high-impact, peer-reviewed international journals and has presented at several scientific conferences. At Eurofins Advinus he has been instrumental in advancing preclinical research and currently leads the in vivo pharmacology and PK division.